Valiant Laboratories Limited has informed the Exchange about Copy of Newspaper Publication for the Quarter and nine months ended December 31, 2025.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Valiant Laboratories has shared the newspaper publication of its audited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, as required under SEBI LODR rules. The results were approved by the Board on February 11, 2026, and published in Financial Express (English) and Mumbai Lakshadeep (Marathi) on February 13, 2026. On a standalone basis, the company reported Total Income from Operations of ₹15,386.12 lakhs for Q3 FY26 with a Net Profit after Tax of ₹201.54 lakhs and EPS of ₹0.37, compared to a loss after tax and negative EPS of ₹(1.30) in Q3 FY25. On a consolidated basis, Q3 FY26 PAT stood at ₹234.51 lakhs with EPS of ₹0.54. The figures indicate a clear year-on-year turnaround from losses to profits.
The shift from a loss in Q3 FY25 to a profit in Q3 FY26 — both on standalone and consolidated bases — is a positive signal for shareholders and could support near-term sentiment, though detailed revenue and margin trends should be reviewed in the full results.